316 related articles for article (PubMed ID: 29286008)
41. Differential anti-microbial secondary metabolites in different ESKAPE pathogens explain their adaptation in the hospital setup.
Tiwari V; Meena K; Tiwari M
Infect Genet Evol; 2018 Dec; 66():57-65. PubMed ID: 30227225
[TBL] [Abstract][Full Text] [Related]
42. Changes in the incidences of multidrug-resistant and extensively drug-resistant organisms isolated in a military medical center.
Keen EF; Murray CK; Robinson BJ; Hospenthal DR; Co EM; Aldous WK
Infect Control Hosp Epidemiol; 2010 Jul; 31(7):728-32. PubMed ID: 20500036
[TBL] [Abstract][Full Text] [Related]
43. Mutant prevention concentrations of colistin used in combination with other antimicrobial agents against Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates.
Choi MJ; Park YK; Peck KR; Ko KS
Int J Antimicrob Agents; 2014 Nov; 44(5):475-6. PubMed ID: 25443890
[No Abstract] [Full Text] [Related]
44. Antimicrobial Resistance in
Lupo A; Haenni M; Madec JY
Microbiol Spectr; 2018 Jun; 6(3):. PubMed ID: 30101740
[TBL] [Abstract][Full Text] [Related]
45. Hospital-acquired infections at an oncological intensive care cancer unit: differences between solid and hematological cancer patients.
Cornejo-Juárez P; Vilar-Compte D; García-Horton A; López-Velázquez M; Ñamendys-Silva S; Volkow-Fernández P
BMC Infect Dis; 2016 Jun; 16():274. PubMed ID: 27286681
[TBL] [Abstract][Full Text] [Related]
46. Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii.
Tsuji BT; Landersdorfer CB; Lenhard JR; Cheah SE; Thamlikitkul V; Rao GG; Holden PN; Forrest A; Bulitta JB; Nation RL; Li J
Antimicrob Agents Chemother; 2016 Jul; 60(7):3913-20. PubMed ID: 27067330
[TBL] [Abstract][Full Text] [Related]
47. Isolation of seven distinct carbapenemase-producing Gram-negative organisms from a single patient.
Creighton J; Heffernan H; Howard J
J Antimicrob Chemother; 2017 Jan; 72(1):317-319. PubMed ID: 27621176
[No Abstract] [Full Text] [Related]
48. Clinical relevance of the ESKAPE pathogens.
Pendleton JN; Gorman SP; Gilmore BF
Expert Rev Anti Infect Ther; 2013 Mar; 11(3):297-308. PubMed ID: 23458769
[TBL] [Abstract][Full Text] [Related]
49. [Microbiological profiles of pathogens causing nosocomial bacteremia in 2011, 2013 and 2016].
Wang X; Zhao C; Li H; Chen H; Jin L; Wang Z; Liao K; Zeng J; Xu X; Jin Y; Su D; Liu W; Hu Z; Cao B; Chu Y; Zhang R; Luo Y; Hu B; Wang H
Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1205-1217. PubMed ID: 30152206
[TBL] [Abstract][Full Text] [Related]
50. Biofilm contamination of high-touched surfaces in intensive care units: epidemiology and potential impacts.
Costa DM; Johani K; Melo DS; Lopes LKO; Lopes Lima LKO; Tipple AFV; Hu H; Vickery K
Lett Appl Microbiol; 2019 Apr; 68(4):269-276. PubMed ID: 30758060
[TBL] [Abstract][Full Text] [Related]
51. Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis.
Vardakas KZ; Voulgaris GL; Samonis G; Falagas ME
Int J Antimicrob Agents; 2018 Jan; 51(1):1-9. PubMed ID: 28669836
[TBL] [Abstract][Full Text] [Related]
52.
Lee B; Yan J; Ulhaq A; Miller S; Seo W; Lu P; She R; Spellberg B; Luna B
mSphere; 2021 Dec; 6(6):e0092021. PubMed ID: 34817233
[TBL] [Abstract][Full Text] [Related]
53. Liquid Extraction Surface Analysis Mass Spectrometry of ESKAPE Pathogens.
Havlikova J; May RC; Styles IB; Cooper HJ
J Am Soc Mass Spectrom; 2021 Jun; 32(6):1345-1351. PubMed ID: 33647207
[TBL] [Abstract][Full Text] [Related]
54. Antibiotic resistance. Epidemiology of resistance in intensive therapy units (ITUs).
Fraise AP
J Med Microbiol; 1997 Jun; 46(6):447-9. PubMed ID: 9379471
[No Abstract] [Full Text] [Related]
55. Intravenous colistin administration in neonates.
Jajoo M; Kumar V; Jain M; Kumari S; Manchanda V
Pediatr Infect Dis J; 2011 Mar; 30(3):218-21. PubMed ID: 21245777
[TBL] [Abstract][Full Text] [Related]
56. Comparison of trends of resistance rates over 3 years calculated from results for all isolates and for the first isolate of a given species from a patient.
Lee SO; Cho YK; Kim SY; Lee ES; Park SY; Seo YH
J Clin Microbiol; 2004 Oct; 42(10):4776-9. PubMed ID: 15472340
[TBL] [Abstract][Full Text] [Related]
57. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
[TBL] [Abstract][Full Text] [Related]
58. Next science wound gel technology, a novel agent that inhibits biofilm development by gram-positive and gram-negative wound pathogens.
Miller KG; Tran PL; Haley CL; Kruzek C; Colmer-Hamood JA; Myntti M; Hamood AN
Antimicrob Agents Chemother; 2014 Jun; 58(6):3060-72. PubMed ID: 24637684
[TBL] [Abstract][Full Text] [Related]
59. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature.
Falagas ME; Kopterides P
J Hosp Infect; 2006 Sep; 64(1):7-15. PubMed ID: 16822583
[TBL] [Abstract][Full Text] [Related]
60. Changes in the prevalence of causative pathogens isolated from severe burn patients from 2012 to 2017.
Park JJ; Seo YB; Choi YK; Kym D; Lee J
Burns; 2020 May; 46(3):695-701. PubMed ID: 31630835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
